Structure's GLP-1 obesity pill could compete with others on the market
Alivia Kaylor, MSc
·
2026-06-09
·
via WhatIs
Phase 2 data suggests Structure Therapeutics' GLP-1 pill, aleniglipron, could be a potential competitor in th…
此内容由惯性聚合(RSS阅读器)自动聚合整理,仅供阅读参考。 原文来自 — 版权归原作者所有。